Biolase (BIOLQ) 8-K Regulation FD Disclosure

Fred Furry, COO & CFO

NASDAQ: BLTI

www.biolase.com

April 3-4, 2012 •

New York Palace Hotel, New York City

Exhibit 99.1

Safe Harbor Statement

This

presentation

may

contain

forward-looking

statements

that

are

based

on

our

current

expectations,

estimates

and

projections

about

our

industry

as

well

as

management’s

beliefs

and

assumptions.

Words

such

as

“anticipates,”

“expects,”

“intends,”

“plans,”

“believes,”

“seeks,”

“estimates,”

“may,”

“will,”

and

variations

of

these

words

or

similar

expressions

are

intended

to

identify

forward-looking

statements.

These

statements

include

projections

about

our

future

earnings

and

margins

and

speak

only

as

of

the

date

hereof.

Such

statements

are

based

upon

the

information

available

to

us

now

and

are

subject

to

change.

We

will

not

necessarily

inform

you

of

such

changes.

These

statements

are

not

guarantees

of

future

performance

and

are

subject

to

certain

risks,

uncertainties

and

assumptions

that

are

difficult

to

predict.

Therefore

our

actual

results

could

differ

materially

and

adversely

from

those

expressed

in

any

forward-looking

statements

as

a

result

of

various

factors.

The

important

factors

which

could

cause

actual

results

to

differ

materially

from

those

in

the

forward-looking

statements

include,

among

others,

a

downturn

or

leveling

off

of

demand

for

our

products

due

to

the

availability

and

pricing

of

competing

products

and

technologies,

adverse

international

market

or

political

conditions,

a

domestic

economic

recession,

the

volume

and

pricing

of

product

sales,

our

ability

to

control

costs,

intellectual

property

disputes,

the

effects

of

natural

disasters

and

other

events

beyond

our

control

and

other

factors

including

those

detailed

in

BIOLASE’s

filings

with

the

Securities

and

Exchange

Commission

including

its

prior

filings

on

Form

10-K

and

10-Q.

PAGE

2

BIOLASE is Revolutionizing Surgery in Medicine

•

The Er,Cr:YSGG (2780nm) laser crystal has the highest level of absorption in water in human tissue. 

•

This absorption creates an expansion and vaporization of the water molecules causing a biological

ablation of human tissue with very little trauma or bleeding.

•

Tooth enamel ~5% water, dentin and bone ~25% water, soft tissue ~80% water, and the eye ~90% water. 

How?  Through the science of WaterLase!

PAGE 3

Conventional Surgical Devices include the scalpel, high speed

drill, electrosurge, electric bone saws, and heat generating lasers.

…BIOLASE is NOT Just Another Medical Device Company!

In 2011: Single Product Company

1.

Moved from global exclusive distribution model with

Schein to direct sales and multi-distributor model.

2.

Launched iPlus which EQUALS the speed of a

traditional dental drill. 

3.

Globalized distribution with approvals in Canada,

Korea, Russia, Taiwan, & others.

4.

Launched Biolase DaVinci digital imaging products.

5.

Grew revenues over 85% on a GAAP basis and 98%

excluding irrevocable purchase orders to Schein and

non-recurring royalty revenue.

6.

Expanded global sales footprint with new offices in

China & India and planned offices in UAE & Brazil.

In 2012: Broaden Platform and Product Portfolio

Becoming a Globally Diversified Platform Company

1.

Diversify revenue base to expand addressable markets

and reduce investor risk.

2.

Launched Waterlase MDX line of all tissue lasers. 

3.

Became the exclusive distributor for Cefla’s NewTom line

of cone beam 3D imaging products in North America.

4.

Plan to launch several other new dental products in 2012

and re-launch the iLase with new distribution partners.

5.

Continue clinical development & approval in:

ophthalmology, orthopedics, pain management, podiatry,

and aesthetics.

6.

2012 is a year for execution and resetting investor

expectations …

under promise, over deliver.

PAGE 4

BIOLASE is the World Leader in Laser Dentistry…

…and

the

Dental

Community

is

the

Largest

Medical

Community

in

the

World!

PAGE 5

BIOLASE ~45%

BIOLASE ~45%

Source: iData Research Inc.

US Overall Dental Laser Market:

Hard & Soft Tissue

BIOLASE ~80%

BIOLASE ~80%

Source: Biolase Technology Licensing Reports

US Dental Laser Market:

Hard Tissue

Traditional Dentistry

The painting Cavadenti, the Tooth Puller, by Caravaggio, circa 1608

PAGE 6

Medical:

The

Diolase

10

offers

high

intensity

laser

therapy

in

the

palm of your hand for pain management.

Digital

Imaging:

We

offer

Cefla’s

NewTom

cone

beam

3D

imaging

and a full line of Biolase DaVinci Imaging equipment, including

the D3D cone beam as well as x-ray generators and tablets.

Diode

soft-tissue

dental

lasers:

Our

soft

tissue

lasers

include the ezLase total diode solution, which offers

power and portability, and the revolutionary iLase, a

portable diode laser with no foot pedal, power cord, or

external controls.

Current Line of BIOLASE Products

PAGE 7

All-tissue

dental

lasers:

Our

all-tissue

lasers

include

our

new

flagship

laser,

the

revolutionary WaterLase iPlus, and the WaterLase MDX.

Alternative and Advanced Hi-Tech Dentistry

Atraumatic Pediatric Tooth Extraction

The aiming beam on

the WaterLase does

not cut the tissue or

generate any heat. 

The tissue is cut

biologically, with little

or no pain, by

energizing water at

the molecular level.

Using BIOLASE WaterLase Systems, including our new WaterLase iPlus System:

PAGE 8

The iPlus features

an intuitive, touch-

based computer

screen, similar to a

tablet personal

computer.  It is

designed to allow for

remote servicing and

software upgrades.

WaterLase High Speed Cutting

PAGE 9

WaterLase Side by Side with Drill

WaterLase Soft Tissue Lingual Frenectomy

Why BIOLASE WaterLase Technology in Dentistry?

Traditional

high-speed

drills

work

by

FRICTION

which

creates

HEAT

which

causes

PAIN. 

This PAIN

necessitates injections of ANESTHESIA which results in PAIN and

NUMB LIPS. 

In addition, the lack of feeling from the numbing injections can

lead to THERMAL DAMAGE

which can lead to PULPAL DEATH and result in a ROOT CANAL.

The traditional high-speed drill

also causes VIBRATION, which causes PAIN

and leads to

MICROFRACTURES.  These MICROFRACTURES allow BACTERIA to penetrate the tooth

which causes further DECAY and the FRACTURING of teeth.

High

speed

drills

also

require

the

use

of

BURS

which

even

after

autoclaving

have a 15% chance of carrying pathogenic micro-organisms.  Needles

and files can also carry bacteria.  That means in traditional dentistry the

patient has a 1 in 6 chance of cross contamination.

WaterLase energy

does not create heat or vibration so there is NO PAIN.  Further, the

WaterLase is bactericidal, antiviral and essentially eliminates the risk of cross

contamination.

PAGE 12

Why Dentists Should Buy a WaterLase System?

•

WaterLase technology enables traditional dentists to perform procedures that they currently refer out to

specialists or current WaterLase dentists, for example:

•

Gingivectomy = $160

•

Perio Treatment = $375

•

Hard-tissue Crown Lengthening = $520

•

Herpetic or Aphthous Ulcer = $308

•

Frenectomy = $355

•

With no anesthesia, the WaterLase also increases efficiency and allows the dentist to work in multiple

quadrants in a single visit.

•

This equates to $250-$750 per day in additional revenue.  These procedures are easy to learn and

training is included in the cost..

Monthly Lease Payment

New Monthly Revenue Generated

Approx. $1,200

$5,000 –

$15,000

PAGE 13

A dentists’

return on investment can

be between ~500% and ~1,500%!

…the tremendous Return on Investment!

$50B to $100B WaterLase Market Opportunity

The WaterLase’s global market opportunity is immense…

because the dental community is the largest medical

community in the world.

•

176,000

dentists

in

the

US

and

Canada.¹

•

Over 1.2 million dentists in 134 countries and growing

rapidly

in

emerging

economies.²

•

19,000 systems in over 11,000 practices.

•

Every 1% of further market penetration, just with the

WaterLase, is equal to an opportunity of well over $600

million in revenues!

Estimated total global market of 1,200,000,

which is growing rapidly due to new markets

such as China, India, and Indonesia.

19,000

3

systems

sold

worldwide.

1. American Dental Association.  2. World Federation of Dentistry.  3. 1998-present over 19,000 BIOLASE systems sold.

PAGE 14

Our current market penetration is approximately

3% in the US and slightly less than 1% internationally! 

1. Dental Health Magazine  2. Dental Burs and Endodontic Files: Are Routine Sterilization Procedures Effective?:

Archie Morrison, DDS, MS, FRCD(C); Susan Conrod, DDS JCDA •

www.cda-adc.ca/jcda •

February 2009, Vol. 75,

No. 1.  3. Contaminated dental instruments: Smith A, Dickson M, Aitken J, Bagg J.J Hosp Infect. 2002 Jul;51(3):233-

5.  4. The antimicrobial efficacy of the erbium, chromium:yttrium-scandium-gallium-garnet laser with radial emitting

tips on root canal dentin walls infected with Enterococcus faecalis: Wanda Gordon, DMD, Vahid A. Atabakhsh, DDS,

Fernando Meza, DMD, Aaron Doms, DDS, Roni Nissan, DMD, Ioana Rizoiu, MS and Roy H. Stevens, DDS, MS

JADA 2007; 138(7): 992-1002.   5. The Bacterial Challenge: Time to React.  A call to narrow the gap between multi-

drug resistant bacteria in the EU and the development of new antibacterial agents., ECDC/EMEA Joint Working

Group, Stockholm, Sweden, September, 2009.

Warning:

Patients Urged to Ask their Dentists

About the Risk of Cross Contamination!

Cross

contamination

is

a

huge

threat:

1,2,3,4

•

The CDC defines cross-contamination as the

act of spreading bacteria and viruses from one

surface to another. Blood-borne viruses have

the ability to live on objects and surfaces for as

long as a week.

•

Sterilization techniques used for dental burs

used with high speed drill and endodontic files

are not effective.  This is a serious health

threat!

•

Many bacteria are becoming more and more

resistant to antibiotics.

5

PAGE 15

The Bacterial Challenge

Antibiotic resistance adversely impacts the health of millions of

patients every year.  Of the patients receiving antibiotics, 50%

receive unnecessary or redundant therapy, resulting in overuse of

antibiotics.¹

Resistance to antibiotics is high among bacteria that cause serious

infections in humans and reaches 25% or more in several EU 

Member States.²

Each year, about 99,000 patients in the US die from hospital

acquired infections³

and 25,000 patients in the EU die from an

infection related to multidrug-resistant bacteria.²

Mortality rates of one resistant strain MRSA in the U.S. exceeded the

combined

death

toll

of

AIDS,

tuberculosis,

and

hepatitis

B.¹

1. Centers for Disease Control and Prevention. Delivering safe care for patients: all healthcare providers play a role., November 15, 2011.  Source:

http://www.cdc.gov/getsmart/healthcare/learn-from-others/factsheets/hc_providers.html.

2.

The

Bacterial

Challenge:

Time

to

React.

A

call

to

narrow

the

gap

between

multi-drug

resistant

bacteria

in

the

EU

and

the

development

of

new

antibacterial

agents.,

ECDC/EMEA

Joint

Working

Group,

Stockholm,

Sweden,

September,

2009.

3.

Klevens

RM,

Edwards

JR,

Richards CL, Horan TC.  Estimating Health-Care Infections and Deaths in US Hospitals, 2002.  Public Helth Reports 2007; 122: 160-166.

WaterLase MD™

reduced E. faecalis 2.86

times more effectively than NaOCl³

1.

Dental

Burs

and

Endodontic

Files:

Are

Routine

Sterilization

Procedures

Effective?:

Archie

Morrison,

DDS,

MS,

FRCD(C);

Susan

Conrod,

DDS

JCDA

•

www.cda-adc.ca/jcda

•

February

2009,

Vol.

75,

No.

1.

2.

Contaminated

dental

instruments:

Smith A, Dickson M, Aitken J, Bagg J.J Hosp Infect. 2002 Jul;51(3):233-5.  3. The antimicrobial efficacy of the erbium, chromium:yttrium-scandium-gallium-garnet laser with radial emitting tips on root canal dentin walls infected with Enterococcus

faecalis: Wanda Gordon, DMD, Vahid A. Atabakhsh, DDS, Fernando Meza, DMD, Aaron Doms, DDS, Roni Nissan, DMD, Ioana Rizoiu, MS and Roy H. Stevens, DDS, MS JADA 2007; 138(7): 992-1002.  4. Dentaltown Research: Endodontics;

Survey, October 2011, dentaltown.com.

Burs and Endo Files:

•

15% of “sterilized”

burs and up to 76% of “sterilized”

endodontic

files

carry

pathogenic

micro-organisms.

1, 2

•

Complex and rugged bur surface difficult to sterilize.

•

Autoclaving fails 15% of the time to decontaminate burs

1

•Only 32% of endodontic engine-driven files are replaced

after

every

case

and

36%

after

every

other

case.

4

WaterLase Tips:

•

Smooth tip surface does not harbor debris or bacteria

like abrasive surface of burs or files.

•

YSGG laser energy is bacteriacidal.

3

•

Single-use, disposable tips that work without the need

to contact tissue.  Also eliminates accidental sticks with

contaminated burs.

BIOLASE is entering a new dental category utilizing WaterLase technology as

it essentially eliminates the risk of cross contamination and contagion:

PAGE 17

Eliminating the Risk of Cross Contamination

Current

Status:

BIOLASE

has

a

tremendous

IP

portfolio

with

285

issued

and

pending

patents, 70% of which are related to our core WaterLase (Er,Cr:YSGG) technology and

medical lasers.

Filing

costs

and

maintenance

are

closely

monitored.

Funding

for

redundant

patents

and

patents with a low-probability for issuance are stopped.

Patent Portfolio

Issued

Pending

Total

U.S.

84

53

137

International

77

71

148

Total

161

124

285

PAGE 18

Patented laser toothbrush for home use:

•

BIOLASE

is

currently

engaged

in

discussions

with

The

Proctor

and

Gamble

Company

(“P&G”)

to

develop

a laser toothbrush for home use using our patents which will whiten teeth, disinfect teeth and gums, bio-

stimulate

teeth

and

gums,

relieve

pain,

and

perform

photodynamic

therapy.

New lasers:

•

BIOLASE introduced the WaterLase MDX line of all-tissue lasers in February 2012 and plans to continue

to offer additional all-tissue WaterLase products in the future that complement the iPlus.

•

We are planning to re-launch the iLase, our handheld diode laser with several new options and

applications.

•

We are also currently engineering more powerful diode soft-tissue lasers for launch in 2012.

New Imaging products:

•

In February 2012, BIOLASE became the exclusive North American distributor for Cefla’s NewTom cone

beam

3D

imaging

products,

thereby

complementing

its

large

family

of

BIOLASE

DaVinci

Imaging

products. 

Further Opportunities to Expand in Dentistry

PAGE 19

Digital Imaging

Cone

Beam

Computed

Tomography

(CBCT)

3D

Imaging:

We

offer

the

Cefla

NewTom VGi and the BIOLASE DaVinci D3D digital CBCTs.  These systems are a vast

improvement over traditional x-ray imaging technologies and offer tremendous clinical

and

diagnostic

advantages

to

dentists.

CBCTs

allow

dentists

to

“see

more”

which,

when

coupled with our WaterLase technology, allows dentists to “do more.”

X-Ray

Generators:

The

BIOLASE

DaVinci

iGen

x-ray

generator

offers

a

unique

ball-

joint and brake assist for optimal positioning.

Portable

X-ray

Tablet:

The

BIOLASE

DaVinci

iTab

x-ray

tablet

allows

for

immediate

access to x-ray images.  It offers wireless synchronization to operatory workstations. 

Intra-oral

Camera:

The

BIOLASE

DaVinci

iView

is

a

progressive

scan

intra-oral

camera that can take live and still images.  This is an excellent tool to assist the dentist

in gaining patient treatment acceptance.

•

We expect WaterLase sales to continue grow in 2012, primarily driven by the iPlus and

complemented by our new line of lower priced WaterLase MDX lasers.   With the MDX, as well as

certified, pre-owned MD Turbos, we can now offer a number of price points to match up with a

doctors specific all-tissue laser needs.

•

Disposables and consumables will continue to represent ~20% of total sales.

•

Our BIOLASE DaVinci Imaging and Cefla New Tom digital imaging products significantly expand

our product portfolio and offer dentists a Total Technology Solution where, when coupled with our

industry-leading

WaterLase

technology,

they

can

see

more

and

do

more.

2011 (Projected)

2012 (Projected)

WaterLase Systems

~60%

~60%

Diode Systems

~20%

~15%

Consumables & Other

~20%

~20%

Digital Imaging Products

~0%

~5%

BIOLASE will continue to add new products and diversify in 2012:

Diversification

in 2012

PAGE 21

With our patented WaterLase and diode technologies, we have created

technological

platforms

that

have

the

ability

to

extend

far

outside

of

dentistry.

We

expect

to

greatly

expand

our

addressable

markets

in

the

coming

years

which, we believe, has the potential to  substantially increase our revenues. 

Each

of

these

potential

markets

represents

a

multi-billion

dollar

opportunity.

Ophthalmology:

We

currently

hold

14

issued

and

19

pending

U.S.

and

International

patents

in

four patent families in the field of ophthalmology, giving us a wide range of applications and

coverage.

Our

patented

technology

has

the

capability

to

restore

the

elasticity

of

the

eye

and

allow it to return to normal function, eliminating presbyopia.  Management has established a new

subsidiary, OCULASE, which will own and develop BIOLASE’s ophthalmic assets and

technologies.

In

2012,

we

expect

approval

to

market

treatments

for

glaucoma

and

dry

eyes.

We

expect approval to market WaterLase technology for presbyopia internationally in 2013 and in the

United States in 2014.

2012: Expanding Beyond Dentistry 

PAGE 22

Aesthetics:

We

have

various

FDA

approvals

for

applications

in

dermatology,

plastic

surgery,

and

oculoplastics and are currently investigating options for entering these markets in 2012.

Pain

Management:

We

anticipate

launching

a

new

deep-tissue

hand

piece

and

upgraded

diode

laser for pain therapy in 2012 which will coincide with a new marketing campaign.  Pain therapy

works and we are seeing more high-level athletes seeking treatment.

Podiatry:

We

have

found

that

our

Diolase

10

technology

is

also

very

effective

in

the

treatment

of

nail fungus and we are completing the clinical and regulatory requirements necessary to enter the

market in late 2012.

Orthopedics:

We

are

working

with

several

key

manufacturers

and

universities

to

provide

solutions that are not currently available.  We are investigating opportunities for several

orthopedic applications and anticipate filing several 510(k) applications during 2012.

PAGE 23

2012: Expanding Beyond Dentistry (Continued)

Quarterly Revenues (in Millions)

PAGE 24

2004

2005

2006

2007

2008

2009

2010

2011

Q1-Mar

$      14.5

$      16.8

$      16.9

$      15.1

$      19.0

$       6.6

$       4.4

$      10.6

Q2-Jun

$      14.7

$      14.5

$      15.9

$      18.2

$      18.7

$      14.3

$       5.9

$      12.1

Q3-Sep

$      12.0

$      11.7

$      17.1

$      12.8

$      15.3

$      12.1

$       6.2

$      13.1

Q4-Dec

$      19.1

$      19.0

$      19.8

$      20.8

$      11.6

$      10.4

$       9.7

$      13.1

Quarterly Non-GAAP Net Income (in Millions)

PAGE 25

2004

2005

2006

2007

2008

2009

2010

2011

Q1-Mar

$    0.783

$   (4.015)

$   (1.462)

$   (0.890)

$    0.985

$   (3.763)

$   (4.797)

$    0.153

Q2-Jun

$    1.006

$   (6.222)

$   (1.340)

$   (0.089)

$    1.578

$    3.020

$   (3.657)

$    0.069

Q3-Sep

$   (0.962)

$   (4.820)

$   (0.167)

$   (2.765)

$   (3.551)

$    1.534

$   (2.173)

$   (0.397)

Q4-Dec

$ (23.257)

$   (0.479)

$   (2.466)

$   (0.272)

$   (4.338)

$   (0.888)

$    0.787

$   (1.260)

Chart & Financial History

Federico

Pignatelli

has

served

as

our

CEO

since

August

2010,

and

as

our

Chairman

of

the

Board

and

CEO

since

September 2010.  Mr. Pignatelli is a >5% shareholder and has been active in the Company as a director and

various

other

management

roles

since

1991.

He

also

the

founder,

and

has

served

as

President,

of

the

Art

&

Fashion Group.

Fred

Furry

has

been

our

CFO

since

November

2010

and

our

COO

since

October

2011.

He

has

over

18

years

of

experience specializing in the high-tech and manufacturing industries while working in public accounting,

including

six

years

with

Pricewaterhouse

Coopers.

Mr.

Furry

was

an

audit

partner

with

Windes

&

McClaughry

prior to joining BIOLASE.

Dmitri

Boutoussov

has

over

19

years

developing

laser

technologies

for

dentistry

and

medicine

in

the

U.S.

and

Europe.  He joined BIOLASE in 2000 and was promoted to CTO in October 2010.  Mr. Boutoussov has authored

and co-authored more than 20 U.S. and international patents and patent applications.

Bill

Brown

has

more

than

30

years

of

experience

in

global/medical

device

companies.

He

has

been

with

BIOLASE

since 2002 and was promoted to Vice President of Sales and Marketing in March 2012. 

Rick

Whipp

has

over

30

years

of

experience

in

manufacturing

and

operations.

Mr.

Whipp

joined

BIOLASE

in

July

2011

and

was

promoted

to

Vice

President

of

Operations

in

October

2011.

Prior

to

joining

BIOLASE,

he

spent

13

years with Discuss Dental, currently a division of Philips Electronics. 

Ehab Esmail

joined BIOLASE in August 2011 as our Vice President of Global Regulatory, Clinical, and Quality

Affairs.  He has more than 18 years of experience as a specialist in regulatory affairs in the medical device and

biologics industries.

PAGE 27

Executive Management

BIOLASE Today

Company Headquarters in Irvine, California

PAGE 28

•

We have over 180 employees worldwide.

•

We also have manufacturing capabilities in Floss,

Germany.

•

We have sales offices in the U.S., Floss (Germany),

Madrid (Spain), Shanghai (China), and Mumbai (India),

with expansion planned in Dubai (UAE), and Rio de Janero

(Brazil). We also have training facilities in Charlotte, NC,

and Irvine, CA.

BIOLASE Europe in Floss, Germany

•

Our 57,000 sq. ft. corporate HQ in Irvine houses finance

& administrative, sales, marketing, customer care,

training, manufacturing, and R&D.  This facility can

accommodate growth to $250 million.

•

ISO 9001 certified and FDA GMP with clean room

operations.